Health Care·Health Care Equipment·$12.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.17 | N/A | +96.18% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.17 | N/A | +96.18% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a positive outlook regarding EPS growth. However, they did not provide specific revenue guidance.
Management expressed satisfaction with the EPS performance despite not providing revenue figures.
They emphasized ongoing efforts to innovate and expand product offerings.
Penumbra's strong EPS performance, significantly beating expectations, contributed to a positive stock reaction, with shares rising by 1.74%. Investors may view this as a sign of the company's effective cost management and operational efficiency. However, the lack of revenue details leaves some uncertainty about overall growth prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ENBRIDGE INC
Nov 2, 2018